Microglial activation, white matter tract damage, and disability in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 1, 2017
- Accepted in final form January 11, 2018
- First Published March 6, 2018.
Author Disclosures
- Eero Rissanen, MD, PhD,
- Jouni Tuisku, MSc,
- Tero Vahlberg, MSc,
- Marcus Sucksdorff, MD,
- Teemu Paavilainen, MD, PhD,
- Riitta Parkkola, MD, PhD,
- Johanna Rokka, PhD,
- Alexander Gerhard, MD,
- Rainer Hinz, PhD,
- Peter S. Talbot, MD, PhD,
- Juha O. Rinne, MD, PhD and
- Laura Airas, MD, PhD
- Eero Rissanen, MD, PhD,
NONE
NONE
(1) Teva Finland, speaker honoraria (2) Biogen Idec, speaker honoraria (3) Roche, speaker honoraria
NONE
NONE
NONE
NONE
(1) Merck, consultancy fee
NONE
NONE
NONE
NONE
(1) State research funding, The expert responsibility area of the Turku University Hospital; personal study grant
NONE
(1) Finnish MS Foundation, personal study grant
NONE
NONE
NONE
NONE
NONE
NONE
- Jouni Tuisku, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tero Vahlberg, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marcus Sucksdorff, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Teemu Paavilainen, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Riitta Parkkola, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Johanna Rokka, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Sigrid Juselius Foundation (2) Maud Kuistila Memorial Foundation (3) Emil Aaltonen Foundation (3) Tor, Joe and Pentti Borg Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Alexander Gerhard, MD,
NONE
NONE
NONE
Neuropathology and Applied Neurobiology, memeber of editorial board (since 2013)
NONE
NONE
NONE
NONE
NONE
Grant review board member Alzheimer?s Research UK (since 2016); non commercial, compeensation for travel expenses only for attending the 6 monthly meetings
NONE
GE Healthcare
1)MRC, The UK GENetic Frontotemporal dementia Initiative (UK GENFI), May 15 - Apr 20 , co-investigator 2)European Commission,FP7-HEALTH, INMIND,Project ID: 27885 Imaging of Neuroinflammation in Neurodegenerative Diseases From 2012-03-01 to 2018-02-28,co-investigator 3)MRC, Defining the disturbance in cortical glutamate and GABA function in psychosis, its origins and consequences, Feb 14-Aug 18 co-investigator 4)NIHR, Imaging cerebral neuroinflammation in acute and chronic cerebrovascular disease: a predictor of outcome and biomarker for guiding treatment, 11/14-10/18, co-investigator
NONE
1)PSP Association 2) MJ Fox Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Rainer Hinz, PhD,
NONE
NONE
NONE
Journal of Neuroimaging, Editorial Board member since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no HEALTH-F2-2011-278850 (INMiND)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter S. Talbot, MD, PhD,
NONE
NONE
NONE
Journal of Psychopharmacology, Editorial advisory board member, 2011-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Juha O. Rinne, MD, PhD and
I serve as a consultant neurologist for Clinical Research Services Turku (CRST) Ltd.
NONE
(1) Biogen, speaker honorarium, (2)Novartis, speaker honorarium, (3) Orion-Pharma, speaker honorarium
I currently serve as an associate editor of Journal of Movement Disorders
NONE
NONE
NONE
NONE
NONE
My duties as a consultant for CRST involve participating in contract research with pharmaceutical companies.
NONE
NONE
(1) Academy of Finland, project #310962, Research grant, years 2017-2021
NONE
(1) Sigrid Juselius Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Airas, MD, PhD
(1) Teva (2) Roche (3) Biogen (3) Genzyme (4) Novartis
NONE
(1) Teva, Travel to congress, (2) Genzyme, Travel to congress(3) BiogenIdec, Speaker honoraria (4) Sanofi-Aventis, Speaker honoraria (5)Merck, Speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Merck, (2) Novartis (3)Biogen Idec (4) Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Turku PET Centre (E.R., J.T., M.S., J.R., J.O.R.), Division of Clinical Neurosciences (E.R., M.S., J.O.R., L.A.), Department of Biostatistics (T.V.), and Medical Imaging Centre of Southwest Finland (T.P., R.P.), Turku University Hospital and University of Turku, Finland; Division of Neuroscience and Experimental Psychology (A.G.), University of Manchester, United Kingdom; Department of Nuclear Medicine and Geriatric Medicine (A.G.), University Hospital Essen, Germany; and Wolfson Molecular Imaging Centre (R.H., P.S.T.), University of Manchester, United Kingdom.
- Correspondence
Dr. Rissanen eerris{at}utu.fi
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jeffrey Allen and Dr. Nicholas Purcell
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imagingSvetlana Bezukladova, Jouni Tuisku, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, March 02, 2020 -
Article
Natalizumab treatment reduces microglial activation in the white matter of the MS brainMarcus Sucksdorff, Jouni Tuisku, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, June 07, 2019 -
Articles
Diffusion tensor magnetic resonance imaging in multiple sclerosisM. Filippi, M. Cercignani, M. Inglese et al.Neurology, February 13, 2001 -
Article
High serum neurofilament associates with diffuse white matter damage in MSMaija Saraste, Svetlana Bezukladova, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, December 08, 2020